ライフサイエンスコーパス: nerve sheath tumor

1 3 for angiosarcoma and malignant peripheral-nerve sheath tumor).

2 stinal hyperplasia, and malignant peripheral nerve sheath tumor.

3 annomas of patients with multiple peripheral nerve sheath tumors.

4 -catenin/CTNNA3 in the biology of peripheral nerve sheath tumors.

5 affin-embedded specimens of human peripheral nerve sheath tumors.

6 ysplasia, scoliosis and malignant peripheral nerve sheath tumors.

7 tion between benign and malignant peripheral nerve sheath tumors.

8 t advances in the diagnosis and treatment of nerve sheath tumors.

9 ) mutant fish developed malignant peripheral nerve sheath tumors.

10 ral ganglion-associated malignant peripheral nerve sheath tumors.

11 A total of 398 nerve sheath tumors (185 plexiform and 213 discrete tumo

12 rgo transformation to a malignant peripheral nerve sheath tumor, an aggressive soft-tissue sarcoma.

13 In malignant peripheral nerve sheath tumors and CNS tumors, the cancers traditio

14 way gliomas, as well as malignant peripheral nerve sheath tumors and glioblastomas.

15 eurofibromas as well as malignant peripheral nerve sheath tumors and other malignant tumors, are sign

16 fibrous histiocytomas, malignant peripheral-nerve sheath tumors, and Ewing's sarcoma.

17 myxofibrosarcomas, and malignant peripheral nerve sheath tumors are characterized by complex genomic

18 ated neurofibromas, and malignant peripheral nerve sheath tumors are covered in this review.

19 s are benign Schwann cell-derived peripheral nerve sheath tumors arising sporadically and within neur

20 mas, neurofibromas, and malignant peripheral nerve sheath tumors, as well as behavioral, cognitive, m

21 A novel classification scheme for peripheral nerve sheath tumors in murine models was therefore devis

22 Plexiform neurofibromas are peripheral nerve sheath tumors initiated by biallelic mutation of t

23 revealed that each of 3 malignant peripheral nerve sheath tumor (MPNST) cell lines from NF1 patients

24 /MAPK/AP-1 signaling in malignant peripheral nerve sheath tumor (MPNST) cell lines.

25 een using NF1-deficient malignant peripheral nerve sheath tumor (MPNST) cells.

26 Malignant peripheral nerve sheath tumor (MPNST) is an aggressive soft tissue

27 ved staging systems for malignant peripheral nerve sheath tumor (MPNST) prognostication and managemen

28 ainst neuroblastoma and malignant peripheral nerve sheath tumor (MPNST) xenografts.

29 me risk of developing a malignant peripheral nerve sheath tumor (MPNST).

30 fibromatosis type 1 and malignant peripheral nerve sheath tumor (MPNST).

31 ty of tumors, including malignant peripheral nerve sheath tumors (MPNST) and benign neurofibromas.

32 Malignant peripheral nerve sheath tumors (MPNST) are highly invasive soft tis

33 Malignant peripheral nerve sheath tumors (MPNST) develop in approximately 10%

34 ann cells in benign and malignant peripheral nerve sheath tumors (MPNST) from neurofibromatosis type

35 rt cytotoxic effects in malignant peripheral nerve sheath tumors (MPNST) where estrogen is not involv

36 not been established in malignant peripheral nerve sheath tumors (MPNST) where NF1 mutations also occ

37 evaluation of HDACis in malignant peripheral nerve sheath tumors (MPNST), a class of highly aggressiv

38 that can transform into malignant peripheral nerve sheath tumors (MPNST), a main cause of mortality.

39 d molecular features of malignant peripheral nerve sheath tumors (MPNST).

40 enign neurofibromas and malignant peripheral nerve sheath tumors (MPNST).

41 ng in neurofibromas and malignant peripheral nerve sheath tumors (MPNST).

42 lignant transformation (malignant peripheral nerve sheath tumor; MPNST), its neoplastic nature has be

43 We tested this in mouse malignant peripheral nerve sheath tumors (MPNSTs) and found that 18% of prima

44 ell cycle regulators in malignant peripheral nerve sheath tumors (MPNSTs) and neurofibromas (NFs).

45 erations in a series of malignant peripheral nerve sheath tumors (MPNSTs) and neurofibromas (NFs).

46 Malignant peripheral nerve sheath tumors (MPNSTs) are a type of rare sarcomas

47 Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive neoplasms th

48 Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas wit

49 Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive tumors with

50 Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive, frequently

51 Malignant peripheral nerve sheath tumors (MPNSTs) are devastating sarcomas fo

52 Malignant peripheral nerve sheath tumors (MPNSTs) are genetically diverse, ag

53 Malignant peripheral nerve sheath tumors (MPNSTs) are sarcomas of Schwann cel

54 Malignant peripheral nerve sheath tumors (MPNSTs) are soft tissue sarcomas th

55 ly worse in primary RAS malignant peripheral nerve sheath tumors (MPNSTs) compared with unmatched spo

56 Malignant peripheral nerve sheath tumors (MPNSTs) develop sporadically or in

57 n cell lines from human malignant peripheral nerve sheath tumors (MPNSTs) driven by NF1 loss, HSF1 wa

58 ing, in differentiating malignant peripheral nerve sheath tumors (MPNSTs) from benign neurofibromas (

59 ann cells isolated from malignant peripheral nerve sheath tumors (MPNSTs) overexpress PDGF receptor-b

60 Malignant peripheral nerve sheath tumors (MPNSTs) represent a group of highly

61 Here we report that malignant peripheral nerve sheath tumors (MPNSTs) that arise in zebrafish as

62 e methylome analysis of malignant peripheral nerve sheath tumors (MPNSTs), benign neurofibromas, and

63 its lethal derivative, malignant peripheral nerve sheath tumors (MPNSTs), is thought to result in th

64 ach is being applied to malignant peripheral nerve sheath tumors (MPNSTs), rare Schwann cell-derived

65 in Nf1 and p53 develop malignant peripheral nerve sheath tumors (MPNSTs), which supports a cooperati

66 et of which progress to malignant peripheral nerve sheath tumors (MPNSTs).

67 ntly progress to become malignant peripheral nerve sheath tumors (MPNSTs).

68 cell neoplasms known as malignant peripheral nerve sheath tumors (MPNSTs).

69 form spontaneously into malignant peripheral nerve sheath tumors (MPNSTs).

70 ransformation of NFs to malignant peripheral nerve sheath tumors (MPNSTs).

71 ased risk of developing malignant peripheral nerve sheath tumors (MPNSTs).These cancers are difficult

72 osarcomas (n = 27), one malignant peripheral-nerve sheath tumor (n = 7), 0 rhabdomyosarcoma (n = 2),

73 ase are the development of benign peripheral nerve sheath tumors (neurofibromas), which can progress

74 <.001), intramedullary tumors (P <.001), and nerve sheath tumors (NSTs) (P <.001).

75 omocytoma, and two with malignant peripheral nerve sheath tumor (PNST) that arose in a ganglioneuroma

76 und to be comutated in high-grade peripheral nerve sheath tumors (PNST) in mice.

77 histologically resemble malignant peripheral nerve sheath tumors, rare neoplasms that occur in indivi

78 xiform neurofibromas to malignant peripheral nerve sheath tumors requires additional genetic changes,

79 g degrees of C-->U RNA editing in peripheral nerve-sheath tumor samples (PNSTs) from patients with NF

80 l and plexiform neurofibromas are peripheral nerve sheath tumors that arise frequently in neurofibrom

81 Schwannomas are common peripheral nerve sheath tumors that can cause debilitating morbidit

82 raneural perineuriomas are benign peripheral nerve sheath tumors that cause progressive debilitating

83 Schwannomas are peripheral nerve sheath tumors that often occur in the setting of a

84 pathogenic pathways of malignant peripheral nerve sheath tumors, these mutant zebrafish lines provid

85 n with schwannomatosis) in whom at least one nerve sheath tumor was reliably identified on MR images.

86 chondrosarcoma, and one malignant peripheral nerve sheath tumor) were analyzed.

87 romas, schwannomas, and malignant peripheral nerve sheath tumors, were presented.

88 TGF-beta receptor II in malignant peripheral nerve sheath tumors, which correspond to tumors in the N

89 which included one patient with a metastatic nerve sheath tumor who was stable for 9 months.

90 ype 1, which is characterized by disfiguring nerve sheath tumors with mast cell infiltration, increas